Repaglinide

Drugs of the Future

Volumn 21, Issue 7, 1996, Pages 694-699

  Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CALCIUM; GLIBENCLAMIDE; INSULIN; MITIGLINIDE; NATEGLINIDE; PLACEBO; RECEPTOR SUBTYPE; REPAGLINIDE;

DIET; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENANTIOMER; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; POTASSIUM TRANSPORT; RAT; SHORT SURVEY; STRUCTURE ACTIVITY RELATION;

EID: 0030017465     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.07.364259     Document Type: Short Survey

References (25)

1. Grell, W. (Dr. Karl Thomae GmbH). New solid forms of 2-ethoxy-4-[N-[1-(2-piperidino-phenyl)-3-methyl-1-butyl] amino-carbonylmethyl]benzoic acid, medicines containing them and process for their preparation. AU 8659139, DE 3522604, EP 207331, ES 8802145, JP 87000474.
2. Grell, W., Hurnaus, R., Griss, G., Sauter, R., Rupprecht, E. (Dr. Karl Thomae GmbH). New phenylacetic acid derivs., medicines containing these cpds. and process for their preparation. AU 8537210, DE 3347565, EP 147850, ES 8604544, ES 8604545, ES 8604546, ES 8604547, ES 8604548, ES 8605500, JP 85158171.
3. Grell, W., Greischel, A., Zahn, G., Mark, M., Knorr, H., Rupprecht, E., Müller, U. (Dr. Karl Thomae, GmbH). (S)(+)-2-(Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl] aminocarbonylmethyl]benzoic acid. EP 589874, JP 94508816, WO 9300337.
4. Prous, J.R. Antidiabetic drugs. In: The Year's Drug News - Therapeutic Targets, 1995 Edition, Prous Science Publishers, Barcelona, 1995, 351-60.
5. 3 cells and rat pancreatic β cells. Diabetologia 1995, 38: 1025-32.
6. Frakjaer-Jensen, J., Kofod, H., Godtfredsen, S.E. Mechanism of action of AG-EE 623 ZW, a novel insulinotropic agent. Diabetologia 1992, 35(Suppl. 1): Abst 447.
7. 2+-induced insulin release. Med Sci Res 1995, 23: 371-2.
8. Fuhlendorff, J., Shymko, R., Carr, R.D., Kofod, H. Characterization of the binding sites for the novel anti-hyperglycaemic drug, repaglinide. Diabetes 1995, 44(Suppl. 1): Abst 848.
9. Fuhlendorff, J., Carr, R., Kofod, H., Rorsman, P. The mechanism of action of repaglinide differs to sulphonylureas in murine β cells. Pharmacol Res 1995, 31(Suppl.): 32.
10. Fuhlendorff, J., Carr, R.D., Kofod, H. Repaglinide: Unique mechanism of action in normal and metabolic stressed β cells. Diabetologia 1995, 38(Suppl. 1): Abst 754.
11. Kofod, H., Fuhlendorff, J. Repaglinide compared to glibenclamide in isolated mouse islets by perifusion. Diabetologia 1995, 38(Suppl. 1): Abst 753.
12. Malaisse, W.J., Brasseur, R., Bakkali Nadi, A., Lins, L. Conformation analysis of non-sulfonylurea hypoglycemic agents in the meglitinide family: Identification of a common configuration responsible for their insulinotropic action. Diabetologia 1995, 38(Suppl. 1): Abst 751.
13. Verspohl, E.J., Ammon, H.P.T., Mark, M. Evidence for more than one binding site for sulfonylureas in insulin-secreting cells. J Pharm Pharmacol 1990, 42: 230-5.
14. Malaisse, W.J. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: The meglitinide family. Horm Metab Res 1995, 27: 263-6.
15. Greischel, A., Beschke, K., Rapp, H., Roth, W. Quantitation of the new hypoglycaemic agent AG-EE 388 ZW in human plasma by automated high-performance liquid chromatography with electrochemical detection. J Chromatogr Biomed Appl 1991, 568: 246-52.
16. Perentesis, G.P., Damsbo, P., Müller, P.G., Gawrylewski, H., Bhattacharyya, H. Single dose pharmacokinetics and pharmacodynamics of repaglinide in type II diabetic patients. J Clin Pharmacol 1994, 34(10): Abst 56.
17. Ampudia-Blasco, F.J., Heinemann, L., Bender, R., Schmidt, A., Heise, T., Berger, M., Starke, A.A.R. Comparative dose-related time-action profiles of glibenclamide and a new non-sulphonylurea drug, AG-EE 623 ZW, during euglycaemic clamp in healthy subjects. Diabetologia 1994, 37: 703-7.
18. Owens, D.R., Donockley, W., Robling, M.R., Dolben, J., Luzio, S.D., Godtfredsen, S. A dose-response study of a new (non-sulphonylurea) agent in diet treated patients with non-insulin dependent diabetes mellitus (NIDDM). 5th World Conf Clin Pharmacol Ther (July 26-31, Yokohama) 1992, Abst O-36-01.
19. Profozic, V., Babic, D., Renar, I., Rupprecht, E., Skrabalo, Z., Metolko, Z. Benzole acid derivative hypoglycemic activity in non-insulin dependent diabetic patients. Diabetologia 1993, 36(Suppl. 1): Abst 701.
20. Van Gaal, L.F., Van Acker, K.L., Damsbo, P., De Leeuw, I.H. Metabolic effects of repaglinide, a new oral hypoglycaemic agent in therapy-naive type 2 diabetics. Diabetologia 1995, 38(Suppl. 1): Abst 164.
21. Wolffenbuttel, B.H.R., Nijst, L., Sels, J.P., Menheere, P., Muller, P.G., Nieuwenhuijzen Kruseman, A.C. Metabolic effect of a new oral hypoglycaemic agent, AG-EE 623 ZW, in sulphonylurea (SU) treated type 2 diabetic patients. Diabetologia 1992, 35(Suppl. 1): Abst 774.
22. Wolffenbuttel, B.H.R., Nijst, L., Sels, J.P.J.E., Menheere, P.P.C.A., Müller, P.G., Nieuwenhuijzen Kruseman, A.C. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur J Clin Pharmacol 1993, 45: 113-6.
23. Tronier, B., Marbury, T.C., Damsbo, P., Windfeld, K. A new oral hypoglycaemic agent, repaglinide minimises risk of hypoglycaemia in well controlled NIDDM patients. Diabetologia 1995, 38(Suppl. 1): Abst 752.
24. Tronier, B., Marbury, T.C., Damsbo, P., Windfeld, K. A new oral hypoglycaemic agent, repaglinide minimises risk of hypoglycaemia in well controlled NIDDM patients. Diabetes 1995, 44(Suppl. 1): Abst 261.
25. Novo Nordisk Annual Report 1995.